ライフサイエンスコーパス: sarcoma

1 omyosarcoma (RMS) is a devastating pediatric sarcoma.

2 nt (ADC) values was developed to predict for sarcoma.

3 rmance in detection of recurrent soft-tissue sarcoma.

4 r tumor monitoring of this highly aggressive sarcoma.

5 ed prognostic significance for patients with sarcoma.

6 n 608 tumours across subtypes of soft-tissue sarcoma.

7 essive model of undifferentiated pleomorphic sarcoma.

8 among the most treatment-refractory types of sarcoma.

9 liver, or unclassified malignant soft-tissue sarcoma.

10 ase, primary effusion lymphoma, and Kaposi's sarcoma.

11 es our understanding of the biology of Ewing sarcoma.

12 potential novel therapeutic avenue in Kaposi sarcoma.

13 tcomes in patients with advanced epithelioid sarcoma.

14 hildren and adults with advanced soft tissue sarcoma.

15 o to tissue remodelling processes due to the sarcoma.

16 andard of care treatment for retroperitoneal sarcoma.

17 ry for the detection and characterisation of sarcoma.

18 EZH2 inhibitor, in patients with epithelioid sarcoma.

19 is the most prevalent pediatric soft-tissue sarcoma.

20 rent INI1-negative solid tumours or synovial sarcoma.

21 SHV pathogenesis and development of Kaposi's sarcoma.

22 nt sarcomas resemble the most inflamed human sarcomas.

23 were classified as bone-invasive histiocytic sarcomas.

24 Cancer, and European Clinical Trials in Rare Sarcomas.

25 SRC family kinase inhibitor, have failed in sarcomas.

26 ns (TFFs) are present in ~30% of soft-tissue sarcomas.

27 hy (FSHD), acute lymphoblastic leukemia, and sarcomas.

28 ) are highly genetically complex soft tissue sarcomas.

29 and rhodamine B was reported to cause local sarcomas.

30 to evaluate interreader reproducibility (16 sarcomas; 26 leiomyomas) and impact of reader experience

31 omyomas) and impact of reader experience (29 sarcomas; 30 leiomyomas).

32 nd July 12, 2018, 90 patients (45 with Ewing sarcoma 45 with osteosarcoma) were recruited to the stud

33 The most common diagnoses were Ewing sarcoma (67%) and osteosarcoma (9%).

34 arcinoma of the skin were found after Kaposi sarcoma (685.68) and Merkel cell carcinoma (117.23).

35 Most tumors were primary sarcomas (88.5%), the majority of which were hemangiosar

36 reatment regimens for AIDS-associated Kaposi sarcoma, a frequent contributor to morbidity and mortali

37 ovial sarcoma, epithelioid sarcoma and Ewing sarcoma - all diseases that present in a younger patient

38 ociated with an increased rate of subsequent sarcoma among those who received alkylating agent doses

39 ll lymphoproliferative diseases and Kaposi's sarcoma, an endothelial-cell-driven cancer.

40 s (95% CI 12.4-35.4) for patients with Ewing sarcoma and 31.1 months (24.4-31.7) for patients with os

41 39 (87%) patients with Ewing sarcoma and 42 (93%) patients with osteosarcoma were ass

42 viation], 45 men) with recurrent soft-tissue sarcoma and 63 age-, sex-, and tumor-matched controls wi

43 tromal tumor (GIST) is the most common human sarcoma and arises in the gastrointestinal tract.

44 ficial in pre-clinical models of soft-tissue sarcoma and deserves further exploration in the clinical

45 sheath tumour, synovial sarcoma, epithelioid sarcoma and Ewing sarcoma - all diseases that present in

46 s in one-quarter of children with chest wall sarcoma and is independent of tumor type.

47 e and demonstrate its activity against avian sarcoma and leukosis virus (ASLV).

48 ainst a prototypical avian retrovirus, avian sarcoma and leukosis virus (ASLV).

49 We find that Ewing sarcoma and malignant rhabdoid tumor (MRT), two pediatri

50 ndency on GBAF (ncBAF) complexes in synovial sarcoma and malignant rhabdoid tumors, both of which pos

51 we used intravital microscopy of orthotopic sarcoma and melanoma xenografts.

52 for risk of subsequent neoplasm, especially sarcoma and melanoma, was significant, evidence supporti

53 hologies, including AIDS-associated Kaposi's sarcoma and multicentric Castleman's disease.

54 ty of CX-6258 was validated in several Ewing sarcoma and multiple myeloma cell lines.

55 mor activity in patients with advanced Ewing sarcoma and osteosarcoma and was generally well tolerate

56 and VEGFR2, in patients with advanced Ewing sarcoma and osteosarcoma.

57 sults in several preclinical models of Ewing sarcoma and osteosarcoma.

58 ogenic gammaherpesvirus that causes Kaposi's sarcoma and other lymphoproliferative disorders.

59 (KSHV) is the etiological agent of Kaposi's sarcoma and primary effusion lymphoma (PEL).

60 sistant NB-PDX; and (iv) xenografts of Ewing sarcoma and rhabdomyosarcoma.

61 svirus (KSHV) is causally linked to Kaposi's sarcoma and several lymphoproliferative diseases.

62 ot study involving 10 cases of biopsy-proven sarcoma and we propose a quantitative method to analyse

63 The training set consisted of 51 sarcomas and 105 leiomyomas.

64 asis and may serve as a prognostic factor in sarcomas and beyond.

65 se aberrations are particularly prevalent in sarcomas and haematopoietic malignancies and frequently

66 marker that identifies high-risk soft-tissue sarcomas and is associated with high metastatic potentia

67 The genomic architecture of carcinomas, sarcomas and lymphomas arising in the same animals are s

68 orexia and cachexia (LPS, methylcholanthrene sarcoma, and 5/6 subtotal nephrectomy) to evaluate effic

69 ent survival for benign to low grade tumors, sarcoma, and carcinoma was 100%/100%/100%, 65%/60%/50%,

70 and in situ squamous cell carcinoma, Kaposi sarcoma, and Merkel cell carcinoma.

71 coma, synovial sarcoma, neuroblastoma, Ewing sarcoma, and osteosarcoma) identified expression signatu

72 diated transcriptional deregulation in Ewing sarcoma, and uncover numerous candidate oncogenes which

73 immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cell-rich terti

74 rs, neuroblastoma, Wilms tumour, soft-tissue sarcomas, and bone cancer) by comparing both groups to s

75 hildren and adults with advanced soft tissue sarcoma are poor with traditional therapy.

76 Here, we show that transplant sarcomas are cured by PD-1 blockade and radiotherapy, bu

77 AR DNA-binding protein 43) and FUS (fused in sarcoma) are aggregation-prone RNA-binding proteins that

78 eling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.

79 During the latent phase, Kaposi's sarcoma-associated herpes virus (KSHV) maintains itself

80 lymphoma associated with infection by Kaposi sarcoma-associated herpes virus (KSHV).

81 Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr V

82 Both Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are human gammaher

83 ogens, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are two of the cla

84 idonic acid pathways of the host in Kaposi's sarcoma-associated herpesvirus (KSHV) biology helped dis

85 we addressed whether the oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) deregulates the ac

86 Detectable Kaposi's sarcoma-associated herpesvirus (KSHV) DNA in blood and i

87 9ORF66 and showed that it restricts Kaposi's sarcoma-associated herpesvirus (KSHV) infection.

88 's sarcoma (KS) caused by oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a highly angiog

89 Kaposi's sarcoma-associated herpesvirus (KSHV) is a human oncogen

90 r premature accumulation.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic ga

91 ntly canonical in nature.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with

92 hance antiviral defenses.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is causally linked

93 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiologically a

94 Kaposi sarcoma-associated herpesvirus (KSHV) is necessary but n

95 Kaposi's sarcoma-associated herpesvirus (KSHV) is the causal agen

96 ssion in the oral cavity.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the causal agen

97 Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative a

98 Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative a

99 Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative a

100 Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic a

101 STAT3 signaling pathway.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological

102 The DNA virus Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological

103 s which play important roles in the Kaposi's sarcoma-associated herpesvirus (KSHV) latent and lytic g

104 germinal center B cells, can induce Kaposi's sarcoma-associated herpesvirus (KSHV) lytic replication

105 ts to control KS lesions.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates severa

106 Molecular mechanisms of Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation have

107 Kaposi's sarcoma-associated herpesvirus (KSHV) transcribes a long

108 Kaposi's sarcoma-associated herpesvirus (KSHV) transcription is r

109 However, the role of Kaposi sarcoma-associated herpesvirus (KSHV), also endemic in A

110 r viruses Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), and human papillo

111 ncluding the human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), and the closely r

112 Kaposi sarcoma-associated herpesvirus (KSHV), one of the human

113 n and KS.IMPORTANCE The ability for Kaposi's sarcoma-associated herpesvirus (KSHV), the causative age

114 ole in early childhood infection with Kaposi sarcoma-associated herpesvirus (KSHV), the maternal immu

115 In Kaposi's sarcoma-associated herpesvirus (KSHV), these vTAs are en

116 Here, we show that the Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded LANA prote

117 The Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded latency-as

118 t, unlike glucose-addicted cancers, Kaposi's sarcoma-associated herpesvirus (KSHV)-transformed cells

119 in the TR and viral Bcl-2 promoter of Kaposi sarcoma-associated herpesvirus (KSHV).

120 phoma (PEL) cases are associated with Kaposi sarcoma-associated herpesvirus (KSHV).

121 positive individuals and is caused by Kaposi sarcoma-associated herpesvirus (KSHV).

122 nize late gene promoters.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV; human herpesvirus

123 The Kaposi's sarcoma-associated herpesvirus homologue, ORF61, also bo

124 ith either human cytomegalovirus or Kaposi's sarcoma-associated herpesvirus.

125 an pathogens Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus.

126 IV and advanced stage AIDS-associated Kaposi sarcoma attending 11 AIDS Clinical Trials Group sites in

127 significantly to cell proliferation of Ewing sarcoma both in vitro and in vivo.

128 ctinomycin D, which is used for treatment of sarcoma but rarely for medulloblastoma, was active again

129 genic transcription factor EWS-FLI1 in Ewing sarcoma, but poor pharmacokinetics (PK) and toxicity lim

130 In 21 cutaneous and/or visceral Kaposi's sarcoma cases, occurring in patients living with human i

131 Using a patient-derived sarcoma cell line, we developed a predictive platform fo

132 e but was meanwhile reclassified as an ewing sarcoma cell line.

133 es the level of the RRM2 protein in multiple sarcoma cell lines.

134 LDH inhibitors affected Ewing sarcoma cell viability both in vitro and in vivo by redu

135 synthesis and inhibited the growth of Ewing sarcoma cells in vitro and in vivo in a xenograft.

136 tors (TFs): KLF15, TCF4 and NKX2-2, in Ewing sarcoma cells.

137 o affected control kidney cell lines and the sarcoma cells; only podocytes are significantly less aff

138 cohort of patients with advanced epithelioid sarcoma characterised by loss of INI1/SMARCB1.

139 The Complexity Index in Sarcomas (CINSARC) signature is a transcriptomic marker

140 Patients eligible for the epithelioid sarcoma cohort (cohort 5) were aged 16 years or older wi

141 y regulate gene expression networks in Ewing sarcoma, controlling important signaling pathways for ca

142 tudy defines the mechanism by which Kaposi's sarcoma could be maintained by virus constantly produced

143 mors, including undifferentiated pleomorphic sarcoma, CSF3R expression, a neutrophil signature and ne

144 ibrosarcoma and undifferentiated pleomorphic sarcoma dependent on Skp2, which could provide the basis

145 n, as macroevolution event, favours specific sarcoma development according to the differentiation lin

146 , locally advanced or metastatic epithelioid sarcoma; documented loss of INI1 expression by immunohis

147 ant peripheral nerve sheath tumour, synovial sarcoma, epithelioid sarcoma and Ewing sarcoma - all dis

148 Ewing sarcoma (EwS) is an aggressive childhood cancer likely o

149 We identify Ewing sarcoma (EWS) protein as a novel LTbetaR signaling compo

150 one fold, as well as the C-terminal REM (rat sarcoma exchange motif), CDC25 (cell division cycle 25),

151 ssive and lethal subtype of small round cell sarcoma found predominantly in adolescents and young adu

152 eosarcoma), pneumothorax (one [2%] for Ewing sarcoma, four [9%] for osteosarcoma), and neutropenia (t

153 arcoma), and neutropenia (two [4%] for Ewing sarcoma, four [9%] for osteosarcoma).

154 tromal tumor (GIST) is the most common human sarcoma, frequently characterized by an oncogenic mutati

155 und Improving the differentiation of uterine sarcomas from atypical leiomyomas remains a clinical cha

156 ficient enabled differentiation of malignant sarcomas from atypical leiomyomas, and it may assist ine

157 criteria to differentiate malignant uterine sarcomas from benign atypical leiomyomas.

158 The RNA-binding protein fused in sarcoma (FUS) can form pathogenic inclusions in neurodeg

159 utations in the RNA-binding protein Fused in Sarcoma (FUS) cause early-onset amyotrophic lateral scle

160 The RNA-binding protein fused in sarcoma (FUS) forms physiological granules and pathologi

161 Pathological fused in sarcoma (FUS) inclusions are found in 10% of patients wi

162 Fused in Sarcoma (FUS) is a ubiquitously expressed protein that c

163 Fused in sarcoma (FUS) is a ubiquitously expressed RNA-binding pr

164 tion of the RNA-DNA binding protein fused in sarcoma (FUS) is higher in Itgalpha1-null cells.

165 , which suppresses alpha-synuclein, fused in sarcoma (FUS), and TDP-43 toxicity.

166 nding protein-43 (TDP-43), tau, and fused in sarcoma (FUS).

167 oma recruited from ten centres in the French Sarcoma Group.

168 ked RNA-binding protein called FUS (fused in sarcoma) has been implicated in several aspects of RNA r

169 ck the interaction between vFLIP, a Kaposi's sarcoma herpesviral oncoprotein, and NEMO using small mo

170 om the Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) human DNA tumor viruses.

171 Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpesvirus (KSHV) infection and is thought to o

172 mune system and suggest that patients with a sarcoma immune phenotype similar to transplant tumors ma

173 being the retrovirus causing walleye dermal sarcoma in fish.

174 in treating advanced AIDS-associated Kaposi sarcoma in resource-limited settings.

175 In our study, Kaposi sarcoma in transplanted patients with HIV did not show a

176 ooperate with Kras(G12D) to generate primary sarcomas in mice.

177 Herein, we review those sarcomas in which chromatin pathway alterations drive di

178 Data from tissues surrounding sarcomas indicated very significant variations with the

179 chitecture of mammary tumours, lymphomas and sarcomas induced by high ((56)Fe-ions) or low (gamma) en

180 CIC-DUX4 sarcoma is a highly aggressive and lethal subtype of sma

181 Kaposi's sarcoma is a highly angiogenic tumor that arises from en

182 Ewing sarcoma is a pediatric bone cancer that expresses the ch

183 Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma sub

184 Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpesvirus

185 Ewing sarcoma is characterized by a pathognomonic chromosomal

186 efficacy of radiotherapy for retroperitoneal sarcoma is not established.

187 Kaposi sarcoma is the most common cancer in human immunodeficie

188 ributes to transcription regulation in Ewing sarcoma is unknown.

189 us (KSHV) is the etiologic agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

190 Kaposi sarcoma (KS) can develop following organ transplantation

191 Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarcoma-associ

192 Kaposi sarcoma (KS) had the highest IR (634.7 per 100 000 perso

193 gically associated with endothelial Kaposi's sarcoma (KS) in immunocompromised individuals.

194 Kaposi's sarcoma (KS) is a rare vascular tumor associated with hu

195 Recent studies have suggested that Kaposi sarcoma (KS) rates might be increasing in some racial/et

196 us (KSHV) is the causative agent of Kaposi's sarcoma (KS), an AIDS-defining cancer with abnormal angi

197 rus (KSHV) is the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multi

198 irus (KSHV) is the causal agent for Kaposi's sarcoma (KS), the most common malignancy in HIV/AIDS pat

199 irus (KSHV) is the causal agent for Kaposi's sarcoma (KS), the most common malignancy in people livin

200 irus (KSHV), the causative agent of Kaposi's sarcoma (KS), to establish and maintain latency has been

201 to play a pivotal role in controlling Kaposi sarcoma (KS)-associated herpesvirus (KSHV) and preventin

202 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is tightly li

203 Kaposi sarcoma (KS)-associated herpesvirus (KSHV) subtype depen

204 k KSHV virion production.IMPORTANCE Kaposi's sarcoma (KS)-associated herpesvirus is the causative age

205 ts are common in bladder cancers, paediatric sarcomas, leukaemias, brain tumours and other cancer typ

206 ch with malignant ganglioglioma, epithelioid sarcoma, lymphoepithelial carcinoma, and malignant rhabd

207 treated with the usual posttransplant Kaposi sarcoma management protocol.

208 014, we enrolled 30 patients with trunk/limb sarcomas, melanoma, Merkel-cell carcinoma, and colorecta

209 tate, pancreas, adrenocortical, small bowel, sarcoma, mesothelioma, melanoma, gastric, and germ cell

210 Using multiple murine sarcoma models, we find that the TME induces tumor cells

211 common and increasing workload within the UK Sarcoma multidisciplinary team (MDT) network, and a sour

212 cell (n = 38, 14%), melanoma (n = 33, 12%), sarcoma (n = 18, 7%), and colorectal (n = 12, 5%).

213 he types of tumors were: carcinoma (n = 20), sarcoma (n = 20) and benign to low grade tumor (n = 6).

214 tumors (including rhabdomyosarcoma, synovial sarcoma, neuroblastoma, Ewing sarcoma, and osteosarcoma)

215 paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no risk stratification systems exis

216 Compared with other typical sarcomas, numerous genes of SaC exhibited significant di

217 astic small round cell tumor (DSRCT), a rare sarcoma of adolescents/young adults primarily involving

218 =18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histologi

219 coma protuberans, undifferentiated embryonal sarcoma of the liver, or unclassified malignant soft-tis

220 curring following exenteration for recurrent sarcoma or locally advanced cervical cancer (3.3% each).

221 by Pol II inhibition, senataxin loss, Ewing sarcoma or locus-associated R-loop repression through an

222 tumors, especially in those with metastatic sarcoma or metastatic colorectal cancer.

223 Patients with Ewing sarcoma or osteosarcoma have a median overall survival o

224 hase 2 trial in patients with advanced Ewing sarcoma or osteosarcoma recruited from ten centres in th

225 roups contained either recurrent soft-tissue sarcomas or positive postoperative findings (nonsarcoma)

226 ing disease cohorts: rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Hodgkin lymphoma,

227 sed risks of subsequent bone and soft-tissue sarcomas, particularly after radiotherapy.

228 viral proteins, in HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentr

229 EWS-FLI1, the oncogenic driver of Ewing sarcoma, regulated LDH A (LDHA) expression.

230 Soft-tissue sarcomas represent a heterogeneous group of cancer, with

231 Children with chest wall sarcoma require multimodal therapy including chemotherap

232 embles most human sarcomas, while transplant sarcomas resemble the most inflamed human sarcomas.

233 he immune microenvironment of primary murine sarcomas resembles most human sarcomas, while transplant

234 SRCT, peritoneal rhabdomyosarcoma, and Ewing sarcoma, respectively) received IP (131)I-omburtamab adm

235 age repair pathway have been associated with sarcoma risk and prognosis.

236 published DNA methylation profiles of Ewing sarcoma samples, we show that DNA methylation heterogene

237 of evidence have implicated dysregulated rat sarcoma signaling in the pathogenesis of DCM, we assesse

238 and functional analyses implicating the rat sarcoma signaling protein, SOS1 (Son of sevenless homolo

239 IR, 169; 95% CI, 115 to 239) and soft-tissue sarcomas (SIR, 542; 95% CI, 418 to 692 v SIR, 45.7; 95%

240 ancreatic, colorectal, esophago-gastric, and sarcoma/soft-tissue tumors.

241 sumed first prospective trial of soft tissue sarcoma spanning nearly the entire age spectrum, adding

242 polycomb-marked genomic regions and synovial sarcoma-specific dependency on PRC1 function.

243 ma (HG-MLPS); leiomyosarcoma (LMS), synovial sarcoma (SS), malignant peripheral nerve sheath tumor (M

244 most frequently in liver biliary, melanoma, sarcoma, stomach, and kidney cancers.

245 the histopathologic response of soft-tissue sarcoma (STS) to neoadjuvant isolated limb perfusion (IL

246 tients with advanced, inoperable soft tissue sarcoma (STS).

247 al activity of ATR inhibition in soft tissue sarcomas (STS).

248 Soft tissue sarcomas (STSs) are mesenchymal tumours where cytotoxic

249 ho were enrolled in the European Soft Tissue Sarcoma Study Group (E pSSG) RMS 2005 study.

250 sarcoma is a rare and aggressive soft-tissue sarcoma subtype.

251 In patients with Ewing sarcoma, ten (26%; 95% CI 13-42) of 39 patients had an o

252 cumented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy,

253 ), cervical, endometrial tumors, and uterine sarcomas that are genomically and/or pharmacologically a

254 dentify distinct microenvironments in murine sarcomas that coevolve with the immune system and sugges

255 tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell l

256 oncoprotein (the hallmark driver of synovial sarcoma) that mediates a direct interaction between the

257 types including over 60 malignant variants (sarcomas) that have unique and varied genetic, biologica

258 afish models of leukemias, neural tumors and sarcomas - the most common and difficult childhood cance

259 Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitone

260 ial future approaches for the development of sarcoma therapies based on this emerging understanding o

261 were hypophosphataemia (five [11%] for Ewing sarcoma, three [7%] for osteosarcoma), aspartate aminotr

262 minotransferase increase (two [4%] for Ewing sarcoma, three [7%] for osteosarcoma), palmar-plantar sy

263 FFC-NMR) relaxometry brings for the study of sarcoma to guide future in vivo analyses of patients.

264 ildren (median age 13 years) with chest wall sarcoma treated at seventeen Pediatric Surgical Oncology

265 t a small number of latently infected Kaposi sarcoma tumor cells undergo spontaneous lytic reactivati

266 mphatic endothelial cells, supporting Kaposi sarcoma tumorigenesis and representing attractive therap

267 Multiple cancer types, including Ewing sarcoma tumors, are sensitive to inhibitors of RNR or a

268 In Kaposi sarcoma tumors, SOX18 and PROX1 expression correlated wi

269 chymal stem cells, which give rise to Kaposi sarcoma tumors.

270 nt supporting persistent infection in Kaposi sarcoma tumors.

271 almar-plantar syndrome (three [7%] for Ewing sarcoma, two [4%] for osteosarcoma), pneumothorax (one [

272 l characteristics of a specific histotype of sarcomas: undifferentiated pleomorphic sarcomas with inc

273 rcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) are highly genetically complex soft tissue

274 ibrosarcoma and undifferentiated pleomorphic sarcoma (UPS) lack specific molecular underpinnings, sho

275 sfully inhibits undifferentiated pleomorphic sarcoma (UPS) tumour growth.

276 or (MPNST), and undifferentiated pleomorphic sarcoma (UPS).

277 neoplasms, particularly bone and soft tissue sarcomas, uterine leiomyosarcoma, melanomas, and radioth

278 nine kinase (BRAF) mutation, and Kirsten rat sarcoma viral oncogene homolog gene (KRAS) mutation.

279 hat the oncogenic avian alpharetrovirus Rous sarcoma virus (RSV) Gag protein undergoes transient nucl

280 red drug resistance, and models of high-risk sarcomas, warranting its further development for clinica

281 The median time from HIV infection to Kaposi sarcoma was 20 years.

282 The primary endpoint for Ewing sarcoma was best objective response within 6 months of t

283 e common in white OTRs (P < .001) and Kaposi sarcoma was more common in black OTRs (P < .001).

284 ghted MRI) from 51 patients with soft-tissue sarcoma was used to prospectively assess reproducibility

285 identify new therapeutic targets in CIC-DUX4 sarcoma, we performed chromatin immunoprecipitation sequ

286 d July 7, 2017, 62 patients with epithelioid sarcoma were enrolled in the study and deemed eligible f

287 Head and neck bone and soft-tissue sarcomas were diagnosed beginning in early childhood and

288 mal hamartoma and undifferentiated embryonal sarcoma, which have different origins but similar appear

289 extremity chemotherapy-sensitive soft tissue sarcoma, which were larger than 5 cm in diameter and of

290 t identical treatment fails in autochthonous sarcomas, which demonstrate immunoediting, decreased neo

291 primary murine sarcomas resembles most human sarcomas, while transplant sarcomas resemble the most in

292 ospective study of patients with soft-tissue sarcomas who were imaged from January 2009 to December 2

293 hese challenges, focusing on angiosarcoma, a sarcoma with an annual incidence of 300 cases in the Uni

294 nerve sheath tumor (MPNST) is an aggressive sarcoma with recurrent loss-of-function alterations in p

295 The Cancer Genome Atlas multiomics study on sarcomas with complex genetics to appraise the associati

296 pe of sarcomas: undifferentiated pleomorphic sarcomas with incomplete muscular differentiation.

297 files indicating five discrete categories of sarcoma, with differences attributable to microstructure

298 a exposure and improved efficacy in an Ewing sarcoma xenograft.

299 of IGF1R, suppressing the growth of Ewing's sarcoma xenografts.

300 months) remissions in 80% to 100% of NB and sarcoma xenografts.

301 oma is the most common childhood soft-tissue sarcoma, yet patients with metastatic or recurrent disea